Name | Title | Contact Details |
---|
Vernalis plc is a revenue generating development stage pharmaceutical company with one marketed product, frovatriptan, and a broad pipeline of research and development programmes. The business model is a balance between risk and innovation with the aim of creating value through a focused and disciplined strategy. An exclusive development and licensing agreement with Tris Pharma to develop multiple novel products focussed on the US prescription cough cold market is the platform for Vernalis to build a profitable and cash generative commercial business in the US. These novel products are low risk, late stage and differentiated for an unmet need. Value is also being extracted from the legacy NCE pipeline where the model is to selectively invest and then partner these programmes, earning milestones and royalties as partners progress them at their expense. Vernalis also exploits its significant expertise in fragment and structure based drug discovery by entering into collaborations with larger pharmaceutical companies. Its technologies and capabilities have been endorsed, over the last five years, through collaborations with leading pharmaceutical companies, including Biogen Idec, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis, Servier and Tris Pharma.
Douglas Laboratories is a Pittsburgh, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At Organon, we envision a better and healthier every day for every woman. The diversity of our business provides a sustainable engine of growth so we can identify and invest in solutions for women. Our mission is to deliver impactful medicines and solutions for a healthier every day. We believe the journey to improve women`s health is critical to achieving a healthier world. We are united in our drive to better support the health of women within our company and around the globe. Together, we work toward our goal of finding solutions for the healthcare issues that matter most to her, today and every day.
Indicus Pharma is a Raleigh, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Oryzon’s MISSION is to identify and manipulate biomarkers -genes and proteins- allowing the development of new therapeutic tools in the quest to improve human health – covering unmet clinical needs- and in benefits for our shareholders. Oryzon’s VISION is to become a world leader company in the field of epigenetic medicine and in the development of therapeutic, biological solutions for cancer and neurodegenerative diseases.